Mouse study links early metastasis to systemic inflammation caused by wound healing

April 12, 2018 by Nicole Giese Rura, Massachusetts Institute of Technology
Credit: Steven Lee/Whitehead Institute

According to new research conducted in mice by Whitehead Institute scientists, surgery in breast cancer patients, which while often curative, may trigger a systemic immunosuppressive response, allowing the outgrowth of dormant cancer cells at distant sites whose ability to generate tumors had previously been kept in check by the immune system. Taking a non-steroidal anti-inflammatory drug (NSAID) around the time of surgery may thwart such early metastatic relapse without impeding post-surgical wound healing.

The team's work was published in the April 11 issue of the journal Science Translational Medicine.

"This represents the first causative evidence of having this kind of systemic response," says Jordan Krall, the first author of the paper and a former postdoc in the lab of Whitehead founding member and MIT Professor Robert Weinberg. "Surgery is essential for treating a lot of tumors, especially breast . But there are some side effects of surgery, just as there are side effects to any treatment. We're starting to understand what appears to be one of those potential side effects, and this could lead to supportive treatment alongside of surgery that could mitigate some of those effects."

Although the association between surgery and metastatic relapse has been documented, a causal line between the two has never been established, leading many to consider early metastatic relapse to be the natural disease progression in some patients. Previous studies of breast cancer patients have shown a marked peak in metastatic relapse 12-18 months following surgery. Although the underlying mechanism for such a spike has not been understood, a 2010 retrospective clinical trial conducted in Belgium provides a clue: Breast cancer patients taking an NSAID for pain following tumor resection had lower rates of this early type of metastatic relapse than patients taking opioids for post-surgical pain. Anti-inflammatory drugs also have previously been shown to directly inhibit tumor growth, but Krall and Weinberg thought that the NSAIDs' effects in these studies may be independent of the mechanism responsible for the effects noted in the retrospective clinical trial.

To investigate the causes of early metastatic relapse after surgery, the team created a mouse model that seems to mirror the immunological detente keeping in check dormant, disseminated tumor cells in . In this experimental model, the mice's T cells stall the growth of tumors that are seeded by injected cancer cells. When mice harboring underwent simulated surgeries at sites distant from the tumor cells, tumor incidence and size dramatically increased. Analysis of the blood and tumors from wounded mice showed that wound healing increases levels of called inflammatory monocytes, which differentiate into -associated macrophages. Such macrophages, in turn, can act at distant sites to suppress the actions of T lymphocytes that previously succeeded in keeping the implanted tumors under control. Krall and Weinberg then tested the effects of the NSAID meloxicam (brand name Mobic), thinking that this anti-inflammatory drug might block the effects of immuno-suppressive effects of wound healing. In fact, when mice received the NSAID after or at the time of surgery, the drug prevented a systemic inflammatory response created by the wound healing and the meloxicam-treated mice developed significantly smaller tumors than wounded, untreated mice; often these tumors completely disappeared. Notably, meloxicam did not impede the mice's wound healing.

Still, Weinberg cautions that scientists are just beginning to understand the connections between post-surgical , inflammation, and metastasis.

"This is an important first step in exploring the potential importance of this mechanism in oncology," says Weinberg, a professor of biology at MIT and director of the MIT/Ludwig Center for Molecular Oncology.

Explore further: Gradual release of immunotherapy at site of tumor surgery prevents tumors from returning

More information: Jordan A. Krall et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy, Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aan3464

Related Stories

Gradual release of immunotherapy at site of tumor surgery prevents tumors from returning

March 21, 2018
A new study by Dana-Farber Cancer Institute scientists suggests it may be possible to prevent tumors from recurring and to eradicate metastatic growths by implanting a gel containing immunotherapy during surgical removal ...

Wound healing response promotes breast cancer metastasis in postpartum mice

September 24, 2014
Within the first 5 years after the birth of a child, women are at an increased risk of developing metastatic breast cancer. Women diagnosed with postpartum breast cancer have a decreased disease free survival time compared ...

Fat tissue may impede radiotherapy for breast cancer patients

June 8, 2017
According to research published online in The FASEB Journal, repeated irradiation of breast fat (also known as adipose tissue) produces an inflammatory response that ultimately reduces the efficiency of radiotherapy in breast ...

Circulating tumor cells associated with relapse in late-stage melanoma patients

November 7, 2017
A study revealing a connection between circulating tumor cells (CTCs) and relapse in stage IV melanoma patients points to liquid biopsy as a potential predictor of patients at high risk for disease progression. CTCs, tumor ...

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism

July 6, 2017
(Medical Xpress)—A team of researchers working at the Albert Einstein College of Medicine in the U.S. has found evidence that suggests administering chemotherapy to breast cancer patients prior to surgery can put them at ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.